Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic. 

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.